Journal Article
. 2015 Jul;153(1).
doi: 10.1007/s10549-015-3518-9.

Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing

Megan C Roberts 1 Morris Weinberger  Stacie B Dusetzina  Michaela A Dinan  Katherine E Reeder-Hayes  Melissa A Troester  Lisa A Carey  Stephanie B Wheeler  
Affiliations
  • PMID: 26216535
  •     25 References
  •     9 citations

Abstract

It is unknown whether racial differences exist in adjuvant chemotherapy initiation among women with similar oncotype DX (ODX) risk scores. We examined whether adjuvant chemotherapy initiation varied by race. Data come from the Phase III, Carolina Breast Cancer Study, a longitudinal, population-based study of North Carolina women diagnosed with breast cancer between 2008 and 2014. We used modified Poisson regression and report adjusted relative risk (aRR) and 95% confidence intervals (95%CI) to estimate the association between race and adjuvant chemotherapy initiation across ODX risk groups among women who received the test (n = 541). Among women who underwent ODX testing, 54.2, 37.5, and 8.3% of women had tumors classified as low-, intermediate-, and high-risk groups, respectively. We observed no racial variation in adjuvant chemotherapy initiation. Increasing ODX risk score (aRR = 1.39, 95%CI = 1.22, 1.58) and being married (aRR = 2.92, 95%CI = 1.12, 7.60) were independently associated with an increased likelihood of adjuvant chemotherapy in the low-risk group. Among women in the intermediate-risk group, ODX risk score (aRR = 1.15, 95%CI = 1.11, 1.20), younger age (aRR = 1.95, 95%CI = 1.35, 2.81), larger tumor size (aRR = 1.70, 95%CI = 1.22, 2.35), and higher income were independently associated with increased likelihood of adjuvant chemotherapy initiation. No racial differences were found in adjuvant chemotherapy initiation among women receiving ODX testing. As treatment decision-making becomes increasingly targeted with the use of genetic technologies, these results provide evidence that test results may drive treatment in a similar way across racial subgroups.

Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer.
Stephanie B Wheeler, William R Carpenter, +3 authors, Andrea K Biddle.
Breast Cancer Res Treat, 2011 Aug 16; 131(1). PMID: 21842244    Free PMC article.
Missed opportunities: racial disparities in adjuvant breast cancer treatment.
Nina A Bickell, Jason J Wang, +5 authors, Amber A Guth.
J Clin Oncol, 2006 Mar 22; 24(9). PMID: 16549830
Highly Cited.
Utilization of Oncotype DX in an Inner City Population: Race or Place?
Amber A Guth, Susan Fineberg, +2 authors, Nina A Bickell.
Int J Breast Cancer, 2014 Jan 24; 2013. PMID: 24455283    Free PMC article.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
A modified poisson regression approach to prospective studies with binary data.
Guangyong Zou.
Am J Epidemiol, 2004 Mar 23; 159(7). PMID: 15033648
Highly Cited.
Racial variation in breast cancer treatment among Department of Defense beneficiaries.
Lindsey Enewold, Jing Zhou, +5 authors, Kangmin Zhu.
Cancer, 2011 Jul 19; 118(3). PMID: 21766298    Free PMC article.
When does a difference become a disparity? Conceptualizing racial and ethnic disparities in health.
Paul L Hebert, Jane E Sisk, Elizabeth A Howell.
Health Aff (Millwood), 2008 Mar 12; 27(2). PMID: 18332492
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Dawn L Hershman, Xiaoyan Wang, +3 authors, Alfred I Neugut.
Breast Cancer Res Treat, 2006 Apr 04; 99(3). PMID: 16583264
21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.
Mary Jo Lund, Marina Mosunjac, +7 authors, Ruth M O'Regan.
Cancer, 2011 Jul 02; 118(3). PMID: 21720988
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.
Megan C Roberts, Stephanie B Wheeler, Katherine Reeder-Hayes.
Am J Public Health, 2015 Apr 24; 105 Suppl 3. PMID: 25905855    Free PMC article.
Systematic Review.
Determinants of breast cancer treatment delay differ for African American and White women.
Sasha A McGee, Danielle D Durham, Chiu-Kit Tse, Robert C Millikan.
Cancer Epidemiol Biomarkers Prev, 2013 Jul 05; 22(7). PMID: 23825306    Free PMC article.
Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.
Stephanie B Wheeler, Katherine E Reeder-Hayes, Lisa A Carey.
Oncologist, 2013 Aug 14; 18(9). PMID: 23939284    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy.
R M Bremnes, K Andersen, E A Wist.
Eur J Cancer, 1995 Nov 01; 31A(12). PMID: 8562147
Racial disparities in treatment and survival among women with early-stage breast cancer.
Dawn Hershman, Russell McBride, +4 authors, Alfred I Neugut.
J Clin Oncol, 2005 Sep 20; 23(27). PMID: 16170171
Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer.
J A Hayman, D L Fairclough, J R Harris, J C Weeks.
J Clin Oncol, 1997 Mar 01; 15(3). PMID: 9060570
Marital status and survival in patients with cancer.
Ayal A Aizer, Ming-Hui Chen, +9 authors, Paul L Nguyen.
J Clin Oncol, 2013 Sep 26; 31(31). PMID: 24062405    Free PMC article.
Highly Cited.
Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991-1997.
Xianglin L Du, Charles R Key, Cynthia Osborne.
Breast J, 2004 Aug 26; 10(5). PMID: 15327498    Free PMC article.
Extension of the modified Poisson regression model to prospective studies with correlated binary data.
G Y Zou, Allan Donner.
Stat Methods Med Res, 2011 Nov 11; 22(6). PMID: 22072596
Highly Cited.
Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.
Dawn Hershman, Mitchell Weinberg, +5 authors, Alfred I Neugut.
J Natl Cancer Inst, 2003 Oct 16; 95(20). PMID: 14559877
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period.
Ayal A Aizer, Tyler J Wilhite, +7 authors, Paul L Nguyen.
Cancer, 2014 May 28; 120(10). PMID: 24863392
Highly Cited.
Parity and disparity in first course treatment of invasive breast cancer.
Mary Jo Lund, Otis P Brawley, +3 authors, J William Eley.
Breast Cancer Res Treat, 2007 Jul 31; 109(3). PMID: 17659438
Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006.
Stacey A Fedewa, Elizabeth M Ward, Andrew K Stewart, Stephen B Edge.
J Clin Oncol, 2010 Aug 11; 28(27). PMID: 20697082
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Christopher R Friese, Yun Li, +6 authors, Steven J Katz.
Cancer, 2016 Oct 25; 123(1). PMID: 27775837    Free PMC article.
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Melissa A Troester, Xuezheng Sun, +16 authors, Charles M Perou.
J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859290    Free PMC article.
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer.
Jae-Myung Kim, Jai Min Ryu, +6 authors, Jeong Eon Lee.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963119    Free PMC article.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.